'Gut-on-chip' can predict immunotherapy outcomes for melanoma patients
A team of researchers has developed a "gut-on-chip" (a miniature model of the human intestine on a chip-sized device) capable ...
BioSpace1d
BMS’ Phase III Opdualag Melanoma Fail Could Limit Market Opportunity: Analysts
The failure in adjuvant melanoma could cause BMS and Opdualag to miss out on a market opportunity that is nearly twice as large as its current approved indication, according to analysts.
FiercePharma1d
Bristol Myers Squibb comes up short in bid to expand Opdualag in melanoma
Upon Opdualag’s approval in 2022 as a first-in-class cancer immunotherapy, Bristol Myers Squibb was anxious to explore its potential in a variety of indications. | Bristol Myers Squibb is striking out ...
How a mole could turn to BRAIN CANCER after Teddi Mellencamp diagnosis
Real Housewives of Beverly Hills star Teddi Mellencamp, 43, was diagnosed 'multiple' brain tumors that may have been caused ...